T1	Participants 359 442	women with operable breast cancer with histologically positive axillary lymph nodes
T2	Participants 447 518	fully and partially evaluable patients with a 68-month median follow-up
T3	Participants 563 582	172 receiving CMFVP
T4	Participants 594 627	186 women given L-PAM (p = 0.002)
T5	Participants 682 725	all subsets regardless of menopausal status
T6	Participants 739 794	women who were premenopausal and had 1-3 positive nodes
